Nexstim Plc: Managers’ Transactions, Forss
Company Announcement, Helsinki, 22 May 2023 at 12:20PM(EEST)
Nexstim Plc: Managers’ Transactions, Forss
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers’ transactions as follows:
Person subject to the notification requirement
Name: Martin Forss
Position: Member of the Board/Deputy member
Issuer: Nexstim Oyj
LEI: 743700S7ZI0LNMHZ6Y27
Notification type: INITIAL NOTIFICATION
Reference number: 32098/5/4
____________________________________________
Transaction date: 2023-05-19
Outside a trading venue
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Name of the instrument: 2023H
Nature of transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 8500 Unit price: 0 EUR
Aggregated transactions (1):
Volume: 8500 Volume weighted average price: 0 EUR
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
The Company’s Certified Advisor is Erik Penser Bank.
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®6.5.2024 14:30:00 CEST | Press release
OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen® (rintatolimod), AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. AIM Chief Executive Officer Thomas K. Equels commented, “We remain focused on operational execution and the successful continued production of our commercial-sized manufacturing process for Ampligen represents a critical component of our overall development, commercial and business development strategies. This is an important milestone as we look to advance our pipeline and work toward clinical and commercial success. Our record of successful manufacturing is both important as we seek commercial partners, as well as for establishing Ampligen reserves for ongoing and upcoming clinical trials.” Ampligen is currently being evaluated as
Investeringsforeningen IA Invest, Afdeling Thygesen Global Stock Selection – Endeligt resultat af tegning6.5.2024 14:23:30 CEST | pressemeddelelse
Investeringsforeningen IA Invest havde indledende tegningsperiode i afdeling Thygesen Global Stock Selection (ISIN: DK0062842134) fra den 22. april til og med den 3. maj 2024. Efter opgørelse af tegningsresultatet for afdeling Thygesen Global Stock Selection er det vurderingen, at afdelingen ikke har opnået en tilstrækkelig stor formue til at blive lanceret og optaget til handel på Nasdaq Copenhagen. Der vil som følge heraf ikke blive udstedt andele i afdeling Thygesen Global Stock Selection. Eventuelle henvendelser vedrørende denne meddelelse bedes rettet til undertegnede på telefon 38 14 66 00. Med venlig hilsen Niels Erik Eberhard Direktør
Investeringsforeningen IA Invest, Afdeling Furesø Globale Kvalitetsaktier – Endeligt resultat af tegning6.5.2024 14:20:15 CEST | pressemeddelelse
Investeringsforeningen IA Invest havde indledende tegningsperiode i følgende afdeling fra den 22. april til og med den 3. maj 2024. Endeligt resultat af tegningen fremgår nedenfor: AfdelingISINTegningskursAntal investorerAntal cirkulerende andeleFormue kr.Furesø Globale KvalitetsaktierDK0062842217100,2033425.234 42.608.447 De nye andele vil blive optaget til handel på Nasdaq Copenhagen med første handelsdag den 14. maj 2024. For yderligere information henvises der til henholdsvis foreningens og afdelingens hjemmeside www.iainvest.dk og www.furesoekapital.dk. Eventuelle henvendelser vedrørende denne meddelelse bedes rettet til undertegnede på telefon 38 14 66 00. Med venlig hilsen Niels Erik Eberhard Direktør
Exodus Movement, Inc. Announces Uplist to NYSE American Exchange6.5.2024 14:15:00 CEST | Press release
OMAHA, Neb., May 06, 2024 (GLOBE NEWSWIRE) -- Exodus Movement, Inc. (OTCQX: EXOD) (“Exodus” or the “Company”), the leading self-custodial cryptocurrency software platform, today announced that its common stock has been approved for listing on the NYSE American stock exchange. The Company’s Class A common stock, par value $0.000001 (the “Common Stock”), will begin trading on the NYSE American under its current symbol, “EXOD,” at the open of trading on May 9, 2024. The Common Stock will continue to trade on the OTCQX until the close of market on May 8, 2024. Current stockholders of the Company do not need to take any action prior to the Company’s expected listing on the NYSE American. “Uplisting to the NYSE American marks a significant milestone in our journey. Trading on the NYSE American will allow Exodus to create greater long-term value for our stockholders by increasing our presence within the investor community and, in turn, increase liquidity,” said JP Richardson, CEO and co-found
Wolters Kluwer unveils AI center; Provides direct access to its AI-driven solutions, insights and expertise6.5.2024 14:01:56 CEST | Press release
PRESS RELEASE Wolters Kluwer unveils AI center; Provides direct access to its AI-driven solutions, insights and expertise Alphen aan den Rijn – May 6, 2024 – Wolters Kluwer, a global leader in professional information, software solutions, and services, today unveiled its dedicated AI center. The launch marks the company's ongoing commitment to combining deep domain knowledge with cutting-edge technology such as artificial intelligence (AI), which Wolters Kluwer has been incorporating into its products for the last 10 years. The AI center centralizes the company’s latest AI-insights, research, and AI-driven information solutions in one accessible location, catering to professionals across critical sectors such as health, financial services, legal, ESG, risk, regulatory, and compliance. The site launch includes a recently published fireside chat featuring Wolters Kluwer CEO and Chair of the Executive Board, Nancy McKinstry, on the explosion of AI in the professional sector. Nancy McKinst